Read by QxMD icon Read

Veno occlusive hepatic disease

Eucario Leon-Rodriguez, Monica M Rivera-Franco
Busulfan (Bu), an alkylating agent, has been used in pre-transplant conditioning regimens since the 1950s, due to its potent myeloablative effect. Questions have been raised regarding oral or intravenous formulations, although both are known to be associated with serious side effects, including hepatic veno-occlusive disease, and neurotoxicity. The administration of anticonvulsant prophylaxis has become more common during high-dose Bu-based conditioning regimen; however, anticonvulsants can interfere with Bu pharmacokinetics and may have their own side effects, which can affect the outcome of the transplant...
October 8, 2016: International Journal of Hematology
Batsaikhan Bat-Erdene, Sergelen Orgoi, Erdene Sandag, Ulzii-Orshikh Namkhai, Bat-Ireedui Badarch, Batsaikhan Batsuuri
The sinusoidal obstructive syndrome (SOS) is a complication that usually follows hematopoietic stem cell transplantation. It is also known as veno-occlusive disease, which is a rare complication of living donor liver transplantation (LDLT). Herein, we reported a 34 year-old female patient presenting SOS after LDLT. Its underlying cause was presumed to be associated with liver abscess and subsequent inferior vena cava stenosis. SOS led to graft failure, thus requiring retransplantation with a deceased donor liver graft...
August 2016: Korean Journal of Hepato-biliary-pancreatic Surgery
(no author information available yet)
No abstract text is available yet for this article.
September 12, 2016: Medical Letter on Drugs and Therapeutics
Stephan Kemmner, Mareike Verbeek, Uwe Heemann
Acute kidney injury and long-term renal dysfunction are common problems following bone morrow transplantation (BMT) and highly related to mortality. The frequency and risk of renal dysfunction are directly related to the method of BMT, with myeloablative allogeneic BMT being associated to the highest risk followed by non-myeloablative allogeneic and myeloablative autologous BMT. The type of BMT is, thus, more important than co-factors such as advanced age, comorbidities, or high baseline serum creatinine. The causes for renal failure are multiple and include chemotherapy and high-dose radiation with fluid loss by diarrhea or vomiting, sepsis or nephrotoxic drugs such as calcineurin inhibitors and antimicrobials...
September 2, 2016: Journal of Nephrology
Paola Tocchetti, Elena Tudone, Jean-Francois Marier, Thomas C Marbury, Katie Zomorodi, Mark Eller
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable, potentially life-threatening complication of hematopoietic stem cell transplant conditioning. Severe VOD/SOS, generally associated with multiorgan dysfunction (pulmonary or renal dysfunction), may be associated with >80% mortality. Defibrotide, recently approved in the US, has demonstrated efficacy treating hepatic VOD/SOS with multiorgan dysfunction. Because renal impairment is prevalent in patients with VOD/SOS, this Phase I, open-label, two-part study in adults examined the effects of hemodialysis and severe or end-stage renal disease (ESRD) on defibrotide pharmacokinetics (PK)...
2016: Drug Design, Development and Therapy
Kim M C van Mierlo, Junfang Zhao, Jos Kleijnen, Sander S Rensen, Frank G Schaap, Cornelis H C Dejong, Steven W M Olde Damink
BACKGROUND DATA: Hepatic sinusoidal dilatation (SD) is a histopathological entity that occurs in up to 75% of patients undergoing oxaliplatin-based chemotherapy for colorectal liver metastases (CRLM). OBJECTIVE: To study the influence of SD on outcome after partial hepatectomy in patients with CRLM. METHODS: Medline, Embase, CENTRAL, LILACS and CINAHL were searched for studies published between 01.01.2004 and 09.06.2015 with keywords: "sinusoidal obstruction syndrome", "hepatic veno-occlusive disease", and "Stuart-Bras syndrome"...
September 2016: Surgical Oncology
Hui-Zhu Kang, Xiao-Li Zheng, Zhi-Dong Wang, Dong-Mei Han, Li Ding, Heng-Xiang Wang
OBJECTIVE: To evaluate the morbidity, risk factors, clinical characterisitics, treatments and prognosis of delayed hepatic veno-occlusive disease(HVOD) after haploidentical hematopoietic stem cell transplantation (hi-HSCT). METHODS: The clinical data of 208 patients undergoing hi-HSCT were retrospectively analyzed. RESULTS: Six patients were diagnosed with delayed VOD, among them 4 patients were moderate VOD and 2 patients were severe VOD...
August 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
Micah A Skeens, Jennifer McArthur, Ira M Cheifetz, Christine Duncan, Adrienne G Randolph, Joseph Stanek, Leslie Lehman, Rajinder Bajwa
Veno-occlusive disease (VOD) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). Patients with VOD are often critically ill and require close collaboration between transplant physicians and intensivists. We surveyed members of a consortium of pediatric intensive care unit (PICU) and transplant physicians to assess variability in the self-reported approach to the diagnosis and management of VOD. An internet-based self-administered survey was sent to pediatric HSCT and PICU providers from September 2014 to February 2015...
October 2016: Biology of Blood and Marrow Transplantation
Mary Choy
Defibrotide sodium (Defitelio) for hepatic veno-occlusive disease; emtricitabine/tenofovir alafenamide (Descovy) for human immunodeficiency virus infection; and infliximabdyyb (Inflectra) for Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
July 2016: P & T: a Peer-reviewed Journal for Formulary Management
Amy Christine Brown
BACKGROUND: No current list of potentially life-threatening, hepatotoxic herbs and dietary supplements based on PubMed case studies exists in a summarized tabular form. METHODS: Documented case reports of herbs or dietary supplements appearing to contribute to liver injury were used to create a "Harmful Herb and Dietary Supplement List" of potentially hepatotoxic herbs and dietary supplements (PubMed, 1966 to May, 2015, and cross-referencing). The spectrum of herbal induced liver injuries (HDSILI) researched included elevated liver enzymes, hepatitis, steatosis, cholestasis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, veno-occlusive disease, acute liver failure requiring a liver transplant, and death...
July 8, 2016: Food and Chemical Toxicology
Selim Corbacioglu, Enric Carreras, Mohamad Mohty, Antonio Pagliuca, Jaap Jan Boelens, Gandhi Damaj, Massimo Iacobelli, Dietger Niederwieser, Eduardo Olavarría, Felipe Suarez, Tapani Ruutu, Leo Verdonck, Robin Hume, Bijan Nejadnik, Chinglin Lai, Giorgia Finetto, Paul Richardson
Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable and potentially fatal complication of hematopoietic cell transplantation (HCT) or nontransplantation-associated chemotherapy/radiotherapy. In cases of severe hepatic VOD/SOS, typically defined by associated multiorgan failure (MOF, also known as multiorgan dysfunction), mortality exceeds 80%. Preclinical and early clinical data have provided a rationale for defibrotide treatment in hepatic VOD/SOS. Based on this evidence and in recognition of the dismal prognosis for these patients, defibrotide was made available through an international multicenter compassionate-use program conducted from December 1998 to March 2009...
October 2016: Biology of Blood and Marrow Transplantation
Arin L Madenci, Alyssa Stetson, Christopher B Weldon, Leslie E Lehmann
Hepatic VOD (veno-occlusive disease) is a serious complication of HSCT (hematopoietic stem cell transplantation) and has historically been associated with high mortality. This obstruction to hepatic flow often results in fluid collections in the peritoneal and pleural cavities. Catheter placement to drain ascites or pleural fluid may reduce intra-abdominal hypertension and/or improve respiratory parameters. The safety of these interventions among critically ill, immunocompromised children is unknown. Among 32 HSCT recipients (2000-2012) with severe VOD, we assessed the primary outcome of procedural complication from peritoneal drain placement...
August 2016: Pediatric Transplantation
Elise Button
No abstract text is available yet for this article.
July 2016: Cancer Nursing
Marcelo C Pasquini, Jennifer Le-Rademacher, Xiaochun Zhu, Andrew Artz, John DiPersio, Hugo F Fernandez, Shin Mineishi, Masaru Kamishohara, Jayesh Mehta, Yuki Nakamura, Voravit Ratanatharathorn, Ronald Sobecks, Jeanne Burkart, Christopher Bredeson
Busulfan (Bu)-containing regimens are commonly used in myeloablative conditioning regimens before allogeneic hematopoietic cell transplantation (HCT). Yet, there is considerable variability on how Bu is administered related to frequency (4 times a day [Q6] or daily [Q24]) and combinations with other chemotherapeutic agents (cyclophosphamide [Cy] or fludarabine [Flu]). We performed a prospective cohort study of recipients of Bu-based conditioning according to contemporary practices to compare different approaches (BuCy Q6, n = 495; BuFlu Q24, n = 331; BuCy Q24, n = 96; BuFlu Q6, n = 91) in patients with myeloid malignancies between 2009 and 2011...
August 2016: Biology of Blood and Marrow Transplantation
R R Pol, N Russell, E Das-Gupta, L Watson, L Rachael, J Byrne
No abstract text is available yet for this article.
September 2016: Bone Marrow Transplantation
Jérôme Bouligand, Clémentine Richard, Dominique Valteau-Couanet, Cedric Orear, Lionel Mercier, Romain Kessari, Nicolas Simonnard, Fabienne Munier, Estelle Daudigeos-Dubus, Bassim Tou, Paule Opolon, Alain Deroussent, Angelo Paci, Gilles Vassal
PURPOSE: Busulfan-melphalan high-dose chemotherapy followed by autologous stem cell transplantation is an essential consolidation treatment of high-risk neuroblastoma in children. Main treatment limitation is hepatic veno-occlusive disease, the most severe and frequent extra-hematological toxicity. This life threatening toxicity has been related to a drug interaction between busulfan and melphalan which might be increased by prior disturbance of iron homeostasis, i.e. an increased plasma ferritin level...
August 2016: Pharmaceutical Research
Dominique-Charles Valla, Dominique Cazals-Hatem
Sinusoidal obstruction syndrome (SOS) is characterized by damage to small hepatic vessels affecting particularly sinusoidal endothelium. Damaged sinusoids can be associated with a partial or complete occlusion of small hepatic veins, hence the previous denomination of hepatic veno-occlusive disease (VOD). Exposure to certain exogenous toxins appears to be specific to this condition and is frequently included in its definition. Typical histopathological features of SOS in a liver biopsy specimen are presented in the text...
September 2016: Clinics and Research in Hepatology and Gastroenterology
Sally Arai
In this issue of Blood, Palomo et al provide new insight into the mechanism of action of defibrotide as an endothelial protective agent, while Richardson et al present the encouraging final results of the phase 3 clinical study of defibrotide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement in day +100 survival after hematopoietic cell transplantation (HCT) compared with historical control.
March 31, 2016: Blood
Shalini Shenoy, Alexis A Thompson
Thalassemia major is characterized by severe anemia dependent on red cell transfusions from infancy. Conservative management requires a safe source of compatible blood throughout life, strategies to combat iron overload, monitoring and treatment of transfusion-related complications, and management of cardiac and/or hepatic dysfunction from iron accumulation. Complications can result in premature morbidity and mortality. Stem cell transplantation is curative, but outcomes depend on the availability of a histocompatible donor, recipient age, and disease-related complications...
March 2016: Annals of the New York Academy of Sciences
J De La Serna, J Sanz, A Bermúdez, M Cabrero, D Serrano, C Vallejo, V Gómez, J M Moraleda, S G Perez, M D Caballero, E Conde, J J Lahuerta, G Sanz
The safety and efficacy of a 4-day myeloablative conditioning (MAC) regimen consisting of Bu 3.2 mg/kg and fludarabine 40 mg/m(2)/day for HLA-identical sibling allogeneic hematopoietic cell transplantation (HCT) in myeloid malignancies was investigated in 133 patients (median age, 47 years; range 19-74 years) with de novo AML (60%), secondary AML (20%) or myelodysplastic syndrome (20%). All patients engrafted. Hepatic veno-occlusive disease occurred in five patients (4%), and severe toxicities, mostly mucositis, occurred in twenty-three (17%) patients...
July 2016: Bone Marrow Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"